{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:08:18Z","timestamp":1783822098093,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore women\u2019s experiences following polygenic risk score (PRS) testing for breast cancer risk and to assess the knowledge, attitudes, practices (KAP), and implementation perspectives of medical professionals and healthcare decision-makers in Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Convergent mixed-methods study combining quantitative survey data with qualitative thematic analysis of survey open-ended responses and focus group discussion (FGD) notes. Setting: Swedish healthcare context. Participants: 400 women receiving PRS results for a first Participants Feedback Survey; 289 women for the second Participants Feedback Survey, and 6 medical professionals\/decision-makers for a KAP survey and FGD. Women completed two sequential online feedback surveys post-PRS result disclosure. Professionals completed a KAP survey and participated in an FGD. Quantitative survey data were analysed using descriptive statistics. Qualitative data from open-ended survey questions and FGD notes were analysed using thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants valued participation in PRS testing and receiving PRS-test results, with 87% finding results interesting and 82% finding them valuable. Although most participants found the explanations understandable (approximately 75% in Survey 1 and 82% in Survey 2), qualitative comments indicated that some had difficulty interpreting probabilistic risk information, including participants who self-identified as highly educated or medically trained. Negative emotional impact was generally minimal (85% felt calm), though some women with high PRS risk experienced anxiety. Major unmet needs included clearer explanations, actionable guidance, and better access to follow-up support from healthcare. Professionals were cautiously positive: in the KAP survey, 5 of 6 were familiar with the concept of PRS, but confidence in the health system\u2019s readiness to integrate it was limited. The main barriers raised were the absence of clinical guidelines and the need for evidence of clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Breast cancer PRS testing holds potential for enhancing risk assessment in Sweden. Key challenges for clinical integration include clinician readiness, the development of clear guidelines, and improved participant comprehension and communication. PRS tests should be accompanied with clinical decision support both for patients as well for medical professionals. Addressing these will require person-centered communication tools, robust evidence of clinical utility, well-defined clinical pathways, investments in provider education, and equitable implementation strategies within the Swedish healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-15116-7","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:14:55Z","timestamp":1783761295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practice"],"prefix":"10.1186","volume":"26","author":[{"given":"Sergio","family":"Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Harkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Digkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karakatsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madli","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Padrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kruuv-K\u00e4o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siim","family":"S\u00f5ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Rosenm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeme","family":"T\u00f5nisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3329-6066","authenticated-orcid":false,"given":"Inna","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"4","key":"15116_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362.","journal-title":"Nat Med"},{"key":"15116_CR2","unstructured":"Cancerfonden [Internet]. [cited 2025 Sept 13]. Statistik br\u00f6stcancer. Available from: https:\/\/www.cancerfonden.se\/om-cancer\/statistik\/brostcancer"},{"key":"15116_CR3","doi-asserted-by":"publisher","unstructured":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - Sung\u2009\u2013\u20092021 - CA: A Cancer Journal for Clinicians - Wiley Online Library [Internet]. [cited 2025 Sept 13]. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"15116_CR4","doi-asserted-by":"crossref","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018 July;119(2):141\u201352.","DOI":"10.1038\/s41416-018-0127-5"},{"key":"15116_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.breast.2023.01.003","volume":"67","author":"E Roberts","year":"2023","unstructured":"Roberts E, Howell S, Evans DG. Polygenic risk scores and breast cancer risk prediction. Breast. 2023;67:71\u20137.","journal-title":"Breast"},{"issue":"7678","key":"15116_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature24284","volume":"551","author":"K Michailidou","year":"2017","unstructured":"Michailidou K, Lindstr\u00f6m S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92\u20134.","journal-title":"Nature"},{"issue":"1","key":"15116_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104(1):21\u201334.","journal-title":"Am J Hum Genet"},{"key":"15116_CR8","doi-asserted-by":"publisher","unstructured":"Breast Cancer Risk Genes. \u2014 Association Analysis in More than 113,000 Women | New England Journal of Medicine [Internet]. [cited 2025 Sept 13]. Available from: https:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1913948?url_ver=Z39.88-2003\ud52f_id=ori:rid:crossref.org\ud52f_dat=cr_pub%20%200pubmed.","DOI":"10.1056\/NEJMoa1913948?url_ver=Z39.88"},{"key":"15116_CR9","doi-asserted-by":"crossref","unstructured":"Hingorani AD, Gratton J, Finan C, Schmidt AF, Patel R, Sofat R, et al. Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the Polygenic Score Catalog. BMJ Med [Internet]. 2023 Oct 17 [cited 2025 Sept 13];2(1). Available from: https:\/\/bmjmedicine.bmj.com\/content\/2\/1\/e000554","DOI":"10.1136\/bmjmed-2023-000554"},{"key":"15116_CR10","doi-asserted-by":"crossref","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 July 1;109(7):djw302.","DOI":"10.1093\/jnci\/djw302"},{"issue":"2","key":"15116_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41591-024-02796-z","volume":"30","author":"NJ Lennon","year":"2024","unstructured":"Lennon NJ, Kottyan LC, Kachulis C, Abul-Husn NS, Arias J, Belbin G, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat Med. 2024;30(2):480\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"15116_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13073-025-01524-7","volume":"17","author":"KB Fergus","year":"2025","unstructured":"Fergus KB, Heise RS, Madlensky L, Fiscalini A, Sabacan L, Theiner S, et al. Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial. Genome Med. 2025;17(1):97.","journal-title":"Genome Med"},{"issue":"3","key":"15116_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/genes14030732","volume":"14","author":"A Ayoub","year":"2023","unstructured":"Ayoub A, Lapointe J, Nabi H, Pashayan N. Risk-Stratified Breast Cancer Screening Incorporating a Polygenic Risk Score: A Survey of UK General Practitioners\u2019 Knowledge and Attitudes. Genes. 2023;14(3):732.","journal-title":"Genes"},{"key":"15116_CR14","doi-asserted-by":"crossref","unstructured":"Primary care providers. \u2019 experience and satisfaction with personalised breast cancer screening risk communication: a descriptive cross-sectional study | BMJ Open [Internet]. [cited 2025 Sept 13]. Available from: https:\/\/bmjopen.bmj.com\/content\/15\/5\/e093936.long","DOI":"10.1136\/bmjopen-2024-093936"},{"issue":"1","key":"15116_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13073-022-01117-8","volume":"14","author":"ACF Lewis","year":"2022","unstructured":"Lewis ACF, Perez EF, Prince AER, Flaxman HR, Gomez L, Brockman DG, et al. Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization. Genome Med. 2022;14(1):114.","journal-title":"Genome Med"},{"issue":"12","key":"15116_CR16","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41436-021-01288-6","volume":"23","author":"T Yanes","year":"2021","unstructured":"Yanes T, Meiser B, Kaur R, Young MA, Mitchell PB, Scheepers-Joynt M, et al. Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior. Genet Med. 2021;23(12):2316\u201323.","journal-title":"Genet Med"},{"issue":"1","key":"15116_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41525-024-00407-x","volume":"9","author":"T Yanes","year":"2024","unstructured":"Yanes T, Tiller J, Haining CM, Wallingford C, Otlowski M, Keogh L, et al. Future implications of polygenic risk scores for life insurance underwriting. Npj Genomic Med. 2024;9(1):25.","journal-title":"Npj Genomic Med"},{"key":"15116_CR18","unstructured":"Stratified screening for cancer [Internet]. PHG Foundation. [cited 2025 Sept 13]. Available from: https:\/\/www.phgfoundation.org\/publications\/reports\/stratified-screening-for-cancer\/"},{"issue":"11","key":"15116_CR19","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/cancers16112116","volume":"16","author":"MJ Walker","year":"2024","unstructured":"Walker MJ, Blackmore KM, Chang A, Lambert-C\u00f4t\u00e9 L, Turgeon A, Antoniou AC, et al. Implementing Multifactorial Risk Assessment with Polygenic Risk Scores for Personalized Breast Cancer Screening in the Population Setting: Challenges and Opportunities. Cancers. 2024;16(11):2116.","journal-title":"Cancers"},{"issue":"1","key":"15116_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13073-024-01304-9","volume":"16","author":"R Xiang","year":"2024","unstructured":"Xiang R, Kelemen M, Xu Y, Harris LW, Parkinson H, Inouye M, et al. Recent advances in polygenic scores: translation, equitability, methods and FAIR tools. Genome Med. 2024;16(1):33.","journal-title":"Genome Med"},{"key":"15116_CR21","unstructured":"About. \u2013 BRIGHT [Internet]. [cited 2025 Sept 13]. Available from: https:\/\/brightscreening.eu\/about\/"},{"key":"15116_CR22","doi-asserted-by":"crossref","unstructured":"Lepland A, Tamm M, Padrik P, Paas A, Kruuv-K\u00e4o K, S\u00f5ber S, et al. 1562P The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia. Ann Oncol. 2024 Sept;35(1):S948.","DOI":"10.1016\/j.annonc.2024.08.1624"},{"key":"15116_CR23","unstructured":"Tamm M, Padrik P, Ojamaa K, Paas A, Lepland A, Kruuv-K\u00e4o K, et al. Clinical Implementation Study of Genetic Risk-Based Breast Cancer Screening. Clin Breast Cancer [Internet]. 2025 Sept 10 [cited 2025 Sept 13]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1526820925002484"},{"key":"15116_CR24","volume-title":"Designing and Conducting Mixed Methods Research","author":"JW Creswell","year":"2018","unstructured":"Creswell JW, Plano Clark VL. Designing and Conducting Mixed Methods Research. 3rd ed. Thousand Oaks (CA): SAGE; 2018.","edition":"3"},{"issue":"1","key":"15116_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12920-021-01056-0","volume":"14","author":"DG Brockman","year":"2021","unstructured":"Brockman DG, Petronio L, Dron JS, Kwon BC, Vosburg T, Nip L, et al. Design and user experience testing of a polygenic score report: a qualitative study of prospective users. BMC Med Genomics. 2021;14(1):238.","journal-title":"BMC Med Genomics"},{"issue":"6 Pt 2","key":"15116_CR26","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles and practices. Health Serv Res. 2013;48(6 Pt 2):2134\u201356.","journal-title":"Health Serv Res"},{"issue":"2","key":"15116_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1258\/jhsrp.2007.007074","volume":"13","author":"A O\u2019Cathain","year":"2008","unstructured":"O\u2019Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. J Health Serv Res Policy. 2008;13(2):92\u20138.","journal-title":"J Health Serv Res Policy"},{"issue":"6","key":"15116_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"15116_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8","volume-title":"Naturalistic Inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic Inquiry. Beverly Hills (CA): SAGE; 1985."},{"key":"15116_CR30","doi-asserted-by":"crossref","unstructured":"Padrik P, T\u00f5nisson N, Hovda T, Sahlberg KK, Hovig E, Costa L et al. Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores. Cancers [Internet]. 2025 Mar 21 [cited 2025 Dec 5];17(7). Available from: https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1056","DOI":"10.3390\/cancers17071056"},{"issue":"8","key":"15116_CR31","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.gim.2023.100876","volume":"25","author":"T Yanes","year":"2023","unstructured":"Yanes T, Wallingford CK, Young MA, McInerney-Leo AM, Willis AM, McKnight L, Terrill B, McInerny S, Forrest LE, Cicciarelli L, Williams R, Keane H, James PA. Development and evaluation of a novel educational program for providers on the use of polygenic risk scores. Genet Med. 2023;25(8):100876.","journal-title":"Genet Med"},{"issue":"8","key":"15116_CR32","doi-asserted-by":"publisher","first-page":"e70323","DOI":"10.1111\/cts.70323","volume":"18","author":"R Purvis","year":"2025","unstructured":"Purvis R, Taylor N, Young MA, James P, Forrest LE. Standardization, education, and resourcing: the way forward for implementing polygenic risk scores in hereditary breast and ovarian cancer. Clin Transl Sci. 2025;18(8):e70323.","journal-title":"Clin Transl Sci"},{"key":"15116_CR33","doi-asserted-by":"publisher","first-page":"1577958","DOI":"10.3389\/fmed.2025.1577958","volume":"12","author":"KLA Dunlop","year":"2025","unstructured":"Dunlop KLA, Singh N, Smit AK, Morrow AL, Steinberg J, Cust AE, et al. Building capacity for genomics in primary care: a scoping review of practitioner attitudes, education needs, and enablers. Front Med. 2025;12:1577958.","journal-title":"Front Med"},{"issue":"8","key":"15116_CR34","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41416-023-02156-7","volume":"128","author":"DP French","year":"2023","unstructured":"French DP, McWilliams L, Bowers S, Woof VG, Harrison F, Ruane H, et al. Psychological impact of risk-stratified screening as part of the NHS Breast Screening Programme: multi-site non-randomised comparison of BC-Predict versus usual screening (NCT04359420). Br J Cancer. 2023;128(8):1548\u201358.","journal-title":"Br J Cancer"},{"issue":"15","key":"15116_CR35","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/eurheartj\/ehae649","volume":"46","author":"H Schunkert","year":"2025","unstructured":"Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E, et al. Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: A clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur Heart J. 2025;46(15):1372\u201383.","journal-title":"Eur Heart J"},{"issue":"1","key":"15116_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajhg.2018.11.014","volume":"104","author":"Z Stark","year":"2019","unstructured":"Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, et al. Integrating Genomics into Healthcare: A Global Responsibility. Am J Hum Genet. 2019;104(1):13\u201320.","journal-title":"Am J Hum Genet"},{"key":"15116_CR37","unstructured":"Nationellt v\u00e5rdprogram br\u00f6stcancerscreening. - RCC Kunskapsbanken [Internet]. [cited 2025 Sept 13]. Available from: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/brostcancerscreening\/vardprogram\/"},{"key":"15116_CR38","unstructured":"Socialstyrelsen [Internet]. 2024 [cited 2025 Sept 13]. National Cancer Register. Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-cancer-register\/"},{"issue":"4","key":"15116_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","volume":"51","author":"AR Martin","year":"2019","unstructured":"Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584\u201391.","journal-title":"Nat Genet"},{"key":"15116_CR40","doi-asserted-by":"crossref","unstructured":"Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun 2019 July 25;10(1):3328.","DOI":"10.1038\/s41467-019-11112-0"},{"issue":"3","key":"15116_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.35680\/2372-0247.1234","volume":"4","author":"AS Gallan","year":"2017","unstructured":"Gallan AS, Girju M, Girju R. Perfect ratings with negative comments: Learning from contradictory patient survey responses. Patient Exp J. 2017;4(3):15\u201328.","journal-title":"Patient Exp J"},{"key":"15116_CR42","doi-asserted-by":"crossref","unstructured":"Slunecka JL, van der Zee MD, Beck JJ, Johnson BN, Finnicum CT, Pool R, et al. Implementation and implications for polygenic risk scores in healthcare. Hum Genomics 2021 July 20;15:46.","DOI":"10.1186\/s40246-021-00339-y"},{"key":"15116_CR43","doi-asserted-by":"crossref","unstructured":"Siena LM, Riccio M, Rosso A, Baccolini V, Migliara G, Isonne C, et al. Economic evaluation of Polygenic Risk Scores in healthcare interventions: a systematic review. Eur J Public Health. 2024;34(Suppl 3):ckae144.1948.","DOI":"10.1093\/eurpub\/ckae144.1948"},{"key":"15116_CR44","unstructured":"Genomic Medicine Strategy Plan. 2021\u20132030 | Genomic Medicine Sweden [Internet]. [cited 2026 Jan 2]. Available from: https:\/\/genomicmedicine.se\/en\/about-us\/genomic-medicine-strategy-plan-2021-2030\/"},{"issue":"11","key":"15116_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41571-020-0388-9","volume":"17","author":"N Pashayan","year":"2020","unstructured":"Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17(11):687\u2013705.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15116-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:15Z","timestamp":1783821735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-15116-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15116"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15116-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in the frame of the BRIGHT study, which had ethical approval from the Swedish Ethical Review Authority (Dnr. 2022-03074-01) and informed consent was obtained from all of the participants. The investigators ensured that this study was conducted according to the principles of the Declaration of Helsinki, with relevant regulations, and Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"948"}}